TABLE 3.4 Approved AIDS Medicines as of January 1, 1992

Drug name

Manufacturer

Indication

Bactrim™+ trimethoprim and sulfamethoxazole

Hoffmann-La Roche (Nutley, N.J.)

PCP treatment

Cytovene® ganciclovir (IV)

Syntex (Palo Alto, Calif.)

CMV retinitis

Daraprim®+ pyrimethamine

Burroughs Wellcome (Research Triangle Park, N.C.)

Toxoplasmosis treatment

Diflucan® fluconazole

Pfizer (New York, N.Y.)

Cryptococcal meningitis, candidiasis

Foscavir® foscarnet sodium

Astra Pharmaceutical (Westborough, Mass.)

CMV retinitis

Intron® A+ interferon alfa-2b (recombinant)

Schering-Plough (Madison, N.J.)

Kaposi's sarcoma

NebuPent® aerosol pentamidine isethionate

Fujisawa Pharmaceutical (Deerfield, Ill.)

PCP prophylaxis

Pentam® 300 IM&IV pentamidine isethionate

Fujisawa Pharmaceutical

PCP treatment

PROCRIT®+ epoetin alfa

Ortho Biotech (Raritan, N.J.)

Anemia in Retrovir ®-treated HIV-infected patients

Retrovir® zidovudine (AZT)

Burroughs Wellcome

HIV-positive asymptomatic and symptomatic (ARC, AIDS), pediatric and adult

Roferon®-A+interferon alfa-2a, recombinant/ Roche

Hoffmann-La Roche

Kaposi's sarcoma

Septra®+ trimethoprim and sulfamethoxazole

Burroughs Wellcome

PCP treatment

VIDEX® didanosine (ddl)

Bristol-Myers Squibb (New York, N.Y.)

Treatment of adult and pediatric patients (over 6 months of age) with advanced HIV infection, who are intolerant or who have demonstrated significant clinical or immunologic deterioration during Retrovir® therapy

Zovirax® acyclovir

Burroughs Wellcome

Herpes zoster/simplex

 

SOURCE: Pharmaceutical Manufacturers Association, Washington, D.C.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement